Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 4
2003 2
2004 1
2005 1
2006 1
2007 5
2008 7
2009 17
2010 14
2011 3
2012 11
2013 19
2014 17
2015 18
2016 25
2017 15
2018 17
2019 7
2020 9
2021 22
2022 23
2023 22
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

225 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean se chan kim (32 results)?
Intravascular Imaging-Guided or Angiography-Guided Complex PCI.
Lee JM, Choi KH, Song YB, Lee JY, Lee SJ, Lee SY, Kim SM, Yun KH, Cho JY, Kim CJ, Ahn HS, Nam CW, Yoon HJ, Park YH, Lee WS, Jeong JO, Song PS, Doh JH, Jo SH, Yoon CH, Kang MG, Koh JS, Lee KY, Lim YH, Cho YH, Cho JM, Jang WJ, Chun KJ, Hong D, Park TK, Yang JH, Choi SH, Gwon HC, Hahn JY; RENOVATE-COMPLEX-PCI Investigators. Lee JM, et al. Among authors: kim cj. N Engl J Med. 2023 May 4;388(18):1668-1679. doi: 10.1056/NEJMoa2216607. Epub 2023 Mar 5. N Engl J Med. 2023. PMID: 36876735 Clinical Trial.
Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial.
Pal SK, Albiges L, Tomczak P, Suárez C, Voss MH, de Velasco G, Chahoud J, Mochalova A, Procopio G, Mahammedi H, Zengerling F, Kim C, Osawa T, Angel M, Gupta S, Khan O, Bergthold G, Liu B, Kalaitzidou M, Huseni M, Scheffold C, Powles T, Choueiri TK. Pal SK, et al. Among authors: kim c. Lancet. 2023 Jul 15;402(10397):185-195. doi: 10.1016/S0140-6736(23)00922-4. Epub 2023 Jun 5. Lancet. 2023. PMID: 37290461 Clinical Trial.
Median overall survival was 25.7 months (95% CI 21.5-not evaluable) with atezolizumab-cabozantinib and was not evaluable (21.1-not evaluable) with cabozantinib (HR for death 0.94 [95% CI 0.70-1.27]; p=0.69). Serious adverse events occurred in 126 (48%) of 262 patients trea …
Median overall survival was 25.7 months (95% CI 21.5-not evaluable) with atezolizumab-cabozantinib and was not evaluable (21.1-not evaluable …
Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trial.
Kim CJ, Park MW, Kim MC, Choo EH, Hwang BH, Lee KY, Choi YS, Kim HY, Yoo KD, Jeon DS, Shin ES, Jeong YH, Seung KB, Jeong MH, Yim HW, Ahn Y, Chang K; TALOS-AMI investigators. Kim CJ, et al. Lancet. 2021 Oct 9;398(10308):1305-1316. doi: 10.1016/S0140-6736(21)01445-8. Lancet. 2021. PMID: 34627490 Clinical Trial.
QFR Assessment and Prognosis After Nonculprit PCI in Patients With Acute Myocardial Infarction.
Lee SH, Hong D, Shin D, Kim HK, Park KH, Choo EH, Kim CJ, Kim MC, Hong YJ, Ahn SG, Doh JH, Lee SY, Park SD, Lee HJ, Kang MG, Koh JS, Cho YK, Nam CW, Joh HS, Choi KH, Park TK, Yang JH, Song YB, Choi SH, Jeong MH, Gwon HC, Hahn JY, Lee JM; FRAME-AMI Investigators. Lee SH, et al. Among authors: kim cj. JACC Cardiovasc Interv. 2023 Oct 9;16(19):2365-2379. doi: 10.1016/j.jcin.2023.08.032. JACC Cardiovasc Interv. 2023. PMID: 37821181 Clinical Trial.
Patients were classified by non-IRA QFR values into the QFR 0.80 and QFR >0.80 groups. The primary outcome was a major adverse cardiac event (MACE), a composite of cardiac death, myocardial infarction, and repeat revascularization. ...
Patients were classified by non-IRA QFR values into the QFR 0.80 and QFR >0.80 groups. The primary outcome was a major adverse car …
Psychological Aspects of Glaucoma.
Jeong AR, Kim CY, Kang MH, Kim NR. Jeong AR, et al. Among authors: kim cy. J Nerv Ment Dis. 2016 Mar;204(3):217-20. doi: 10.1097/NMD.0000000000000467. J Nerv Ment Dis. 2016. PMID: 26919300 Review.
We summarize some cautiously recommended psychotherapeutic medications, while also discussing the psychologically adverse effects of antiglaucoma medications....
We summarize some cautiously recommended psychotherapeutic medications, while also discussing the psychologically adverse effects …
Effect of antihypertensive medications on the risk of open-angle glaucoma.
Lee JS, Cha HR, Bae HW, Lee SY, Choi W, Lee SW, Kim CY. Lee JS, et al. Among authors: kim cy. Sci Rep. 2023 Sep 27;13(1):16224. doi: 10.1038/s41598-023-43420-3. Sci Rep. 2023. PMID: 37758842 Free PMC article.
The risks for OAG were found to increase by antihypertensive medication use, but the effects appeared to be small. Further studies are necessary to identify the associations of increased BP, medication and therapeutic effect with OAG....
The risks for OAG were found to increase by antihypertensive medication use, but the effects appeared to be small. Further studies ar …
Are bioactive-rich fractions functionally richer?
Imam MU, Ismail M, Ooi DJ, Azmi NH, Sarega N, Chan KW, Bhanger MI. Imam MU, et al. Among authors: chan kw. Crit Rev Biotechnol. 2016 Aug;36(4):585-93. doi: 10.3109/07388551.2014.995586. Epub 2015 Feb 2. Crit Rev Biotechnol. 2016. PMID: 25641328 Review.
The growing interest in the medicinal properties of plant bioresources stems from concerns of side effects and other adverse effects caused by synthetic drugs. This interest has yielded a better understanding of the roles of plant bioactive compounds in healt …
The growing interest in the medicinal properties of plant bioresources stems from concerns of side effects and other adverse …
225 results